1. Scrip
  2. >>Business

EpiPen Competitor Auvi-Q Relauching With Ultimate Copay: $0

 
• By Emily Hayes

Under kaléo's new access program, patients with insurance will have no co-pay and uninsured people with less than $100,000 income will get the product for free.

Closeup of gift wrapped in red paper and bow at pharmacy counter

Hopefully the date won’t be lost on the marketing department – kaleo Inc. plans to roll out its Auvi-Q epinephrine auto-injector for allergic reactions in the US on Feb. 14, and will be showing some Valentine’s Day love in the form of competitive pricing and a generous patient assistance program.

The launch is likely to get a fair amount of attention, not because of excitement about the product per se,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.